Trial Condition(s):
Angiocardiography
The safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST) (TRUST)
Bayer Identifier:
15454
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
This study is to collect the information of Ultravist® in the patients indicated for the coronary angiography or PCI, like rate of ADR in patients, the dose for different indications, image quality to prove Ultravist the good safety and effectivity
Inclusion Criteria
- Female and male patients who receive Ultravist® for coronary angiography or PCI can be included in the study
Exclusion Criteria
- Patients who are or are suspected in pregnancy or nursery - Patients with the contraindications for Ultravist - Patients with the contraindications for cardiac catheterization
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many Locations, China | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
This is an international, prospective, non-interventional Study, company sponsored, multi-center study. Patients undergo coronary angiography or PCI procedure with Ultravist. The primary objective is to evaluate the safety and tolerability.
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Evaluation of the safety and tolerability of Ultravist® in patients Undergoing cardiac catheterization.Timeframe: 12 months
Secondary Outcome
- Estimation of the image quality of Ultravist®Timeframe: 12 months
Additional Information
Copyright © Bayer
Powered by
